Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

NCT03698994 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03698994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03698994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 14, 2018
Completion date
March 30, 2027
Enrollment
20 (actual)
Sites
107

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, recurrent ependymal tumor, recurrent ewing sarcoma, recurrent glioma, recurrent hepatoblastoma, recurrent histiocytic and dendritic cell neoplasm, recurrent langerhans cell histiocytosis, recurrent malignant germ cell tumor, recurrent malignant solid neoplasm, recurrent medulloblastoma, recurrent neuroblastoma, recurrent non-hodgkin lymphoma, recurrent osteosarcoma, recurrent peripheral primitive neuroectodermal tumor, recurrent primary malignant central nervous system neoplasm, recurrent rhabdoid tumor, recurrent rhabdomyosarcoma, recurrent soft tissue sarcoma, refractory ependymoma, refractory ewing sarcoma, refractory glioma, refractory hepatoblastoma, refractory histiocytic and dendritic cell neoplasm, refractory langerhans cell histiocytosis, refractory malignant germ cell tumor, refractory malignant solid neoplasm, refractory medulloblastoma, refractory neuroblastoma, refractory non-hodgkin lymphoma, refractory osteosarcoma, refractory peripheral primitive neuroectodermal tumor, refractory primary malignant central nervous system neoplasm, refractory rhabdoid tumor, refractory rhabdomyosarcoma, refractory soft tissue sarcoma, wilms tumor